Cassava Sciences, Inc. (SAVA)
PHARMACEUTICAL PREPARATIONS
Cassava Sciences, Inc. (SAVA) was listed on Nasdaq from July 14, 2000 and stopped trading under the symbol SAVA on March 11, 2026.
- Listed On
- Nasdaq
- Listed Since
- July 14, 2000
- Stopped Trading
- March 11, 2026
- Employees
- 30
About Cassava Sciences, Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
Institutional ownership
In 13F filings for the quarter ended March 31, 2026, 1 institution reported holding SAVA, with 422,521 shares worth $714,060 in aggregate. The largest reported holder was Vanguard, with 422,521 shares worth $714,060. Of the 1 largest holders listed below, 1 reduced its position during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Vanguard | 422,521 | $714K | Reduced 0.93% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is SAVA?
Cassava Sciences, Inc. (SAVA) was listed on Nasdaq from July 14, 2000 and stopped trading under the symbol SAVA on March 11, 2026.
Who are the largest institutional holders of SAVA?
In 13F filings for the quarter ended March 31, 2026, the largest reported holders of SAVA were Vanguard.
How many institutions own SAVA?
1 institution reported a position in SAVA for the quarter ended March 31, 2026, worth $714,060 in total.
Did institutions buy or sell SAVA last quarter?
Of the 1 largest reported holders, 1 reduced its position during the quarter. Every reported holder and its change is on the SentiSense ownership page for SAVA.
Every reported institutional holder, plus insider and congressional trades in SAVA, on SentiSense.